Aminopeptidases do not directly degrade tau protein by Chow, K Martin et al.
RESEARCH ARTICLE Open Access
Aminopeptidases do not directly degrade
tau protein
K Martin Chow
*, Hanjun Guan, Louis B Hersh
Abstract
Background: Tau hyperphosphorylation and aggregation to form intracellular neurofibrillar tangles is prevalent in a
number of tauopathies. Thus there is current interest in the mechanisms involved in Tau clearance. It was recently
reported that Tau can be degraded by an aminopeptidase known as the puromycin sensitive aminopeptidase
(PSA). Until now PSA has been reported to only cleave peptides, with the largest reported substrates having 30-50
amino acids. We have studied this unique PSA cleavage reaction using a number of different PSA preparations.
Results: An N-terminally His tagged-PSA was expressed and purified from Sf9 insect cells. Although this PSA
preparation cleaved Tau, product analysis with N and C terminal Tau antibodies coupled with mass spectrometry
showed an endoproteolytic cleavage atypical for an aminopeptidase. Furthermore, the reaction was not blocked by
the general aminopeptidase inhibitor bestatin or the specific PSA inhibitor puromycin. In order to test whether Tau
hydrolysis might be caused by a protease contaminant the enzyme was expressed in E. coli as glutathione
S-transferase and maltose binding protein fusion proteins or in Sf9 cells as a C-terminally His-tagged protein. After
purification to near homogeneity none of these other recombinant forms of PSA cleaved Tau. Further, Tau-cleaving
activity and aminopeptidase activities derived from the Sf9 cell expression system were separable by molecular
sieve chromatography. When tested in a cellular context we again failed to see a PSA dependent cleavage of Tau.
A commercial preparation of a related aminopeptidase, aminopeptidase N, also exhibited Tau cleaving activity, but
this activity could also be separated from aminopeptidase activity.
Conclusion: It is concluded that PSA does not directly cleave Tau.
Introduction
The microtubule-associated protein tau (Tau) is located
primarily in the central nervous system (CNS) and regu-
lates the stability of microtubules. Tau is normally phos-
phorylated in cells with its state of phosphorylation
related to developmental state [1]. Under abnormal con-
ditions Tau becomes hyperphosphorylated, dissociates
from microtubules and forms aggregates [2,3]. There are
a number of neurodegenerative diseases caused by Tau
aggregation collectively termed tauopathies. Among
these is Alzheimer’s disease in which intracellular Tau
aggregates known as tangles are found in the brain and
are believed to contribute to the etiology of the disease
[4-6].
Like other microtubule-associated proteins (MAPs), a
tandem microtubule-binding motif GSxxNxxHxPGGG is
found at the C-terminus of Tau. Isoforms of Tau [7]
have either 3 or 4 of these binding repeats due to alter-
native mRNA splicing of exon 10, which contains the
fourth repeat. Additional variants of Tau are derived by
an N-terminal insertion of exons 2 and 3, by insertion
of only exon 3, and a form with no insertion. Together
these variants result in six Tau isoforms in brain. The
longest isoform (2N4R) contains exons 2 and 3 and 4
binding repeats (441 amino acids), while the shortest
isoform (0N3R) has no N-terminal insert and 3 repeats
(352 amino acids).
Due to its importance in neurodegenerative diseases,
there have been a number of studies of Tau degradation
by proteases such as the proteosome [8], caspase [9],
and thrombin [10]. Recent reports suggest that the pur-
omycin sensitive aminopeptidase (PSA, EC 3.4.11.14)
may regulate Tau levels in vivo [11], and is able to
hydrolyze Tau in vitro [12]. PSA has been characterized
[13-15] as a zinc containing exopeptidase that
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small peptides [16]. It is uniquely sensitive to micromo-
lar concentrations of puromycin, hence its name. PSA is
inhibited by the classical aminopeptidase inhibitor besta-
tin and its analogs. Until now PSA was thought to only
cleave peptides containing no more than 30-50 amino
acids. Thus Tau would be a novel substrate for PSA
being considerably larger than any previously known
substrate. The present study was designed to further
investigate how PSA cleaves Tau; however, the results of
these studies led us to conclude that Tau is not directly
cleaved by PSA or by the closely related aminopeptidase,
aminopeptidase N.
Experimental Procedures
Materials
PMSF, EDTA, bestatin, and o-phenanthroline were pur-
chased from Sigma-Aldrich. Puromycin was from Invi-
trogen (Life Technologies). Monoclonal antibody (5A6)
directed against N-terminal Tau residues 16 to 46 [17]
was obtained from the Developmental Studies Hybri-
doma Bank developed under the auspices of the NICHD
and maintained by The University of Iowa, Department
of Biology. A C-terminal Tau antibody A0024, which is
directed against the C-terminal ~1/3 of Tau, was
obtained from DAKO.
Cloning and Expression of Tau forms
Tau cDNAs in the pcDNA3.1 vector were generously
provided by Dr. M. Hutton (Mayo Clinic, Jacksonville,
Fl.). Two isoforms of Tau were used in this study: the
longest isoform (Tau 2N4R) containing exons 2 and 3
as well as 4 microtubule binding repeats and Tau 0N4R
containing 4 microtubule binding repeats without an
N-terminal insert. For expression in E. coli, the 0N4R
isoform-containing plasmid was amplified by PCR with
the following primers:
Forward primer (5’-AATACATATGGCTGAGCCCCGC),
which contains an Nde 1 site (underlined). Reverse primer
(5’-GAATCTCGAGTTATCACAAACCCTGCTT), which
removes the native stop codon and introduces an Xho 1 site
(underlined) that fuses a C-terminal His6 tag.
PCR products were first subcloned into the pZero2
vector (Invitrogen) for sequencing, and then cloned into
the pET32 vector at Nde1/Xho1 sites for expression.
To generate full-length Tau 2N4R in the pET32 bacter-
ial expression vector, the sequence containing exons 2
and 3 was excised from pcDNA3.1-2N4R and inserted
into pET32b-0N4R using BsiWI and HindIII restriction
sites. These constructs were transformed in E. coli strain
BL21-CodonPlus(DE3)-RP. For expression, cells were
grown at 37°C until an OD600 of 0.5 to 0.7 was reached.
Expression was then induced by the addition of isopropy-
b-D-thiogalactoside (IPTG) to a final concentration of
0.5 mM and carried out for 3-4 hrs at 30°C. Cells were
harvested and washed with PBS. Cell pellets were resus-
pended in 20 mM Tris-HCl, pH 7.5, containing 1 mM
PMSF and 10 μM E-64 and broken with a French press.
The crude homogenate was heated to 85°C for 8 min and
centrifuged at 30,000g at 4°C for 30 min. The supernatant
was then applied to a 5-ml His-Select Nickel affinity col-
umn (Sigma-Aldrich) and washed with the same buffer
without protease inhibitors. Tau was eluted with 100
mM imidazole, concentrated, and the buffer exchanged
to 20 mM Tris buffer pH 7.5, 1 mM DTT using a Milli-
pore centricon. Both heat treated Tau [18] and His
tagged Tau [12] have been shown to retain the ability to
polymerize tubulin.
A stable tetracycline-inducible human Tau (2N4R)
expressing cell line was obtained from Dr. Jeff Kuret
(Ohio State University).
Cloning and Expression of PSA
A full length human PSA cDNA [19] was subcloned
into the pFastbac vector for expression as an N-terminal
hexahistidine PSA (N-His6-PSA) in Sf9 insect cells [20].
To generate a C-terminal hexahistidine PSA (C-His6-
PSA), a C-terminal fragment containing six His residues
was amplified using PSA as a template with the follow-
ing primers:
Forward (5’-TGCCCCCTGTGGATCGACTTGG-3’),
preceding an internal Xho1 site, and reverse (5’-CGA-
TAAGCTTTCAGTGGTGGTGGTGGTGGTGCACTG
TGGGTGG-3’), containing a HindIII site (underlined).
This amplified 901 bp product and the 5’ 1745 bp
fragment were cloned into pFastbac1 using HindIII/
Xho1 and Xho1/BamH1 sites, respectively. The proce-
dures of transposing pFastbac-PSA to bacmid and sub-
sequent baculovirus amplification were performed
according to the manufacturer’s instructions. Three days
after infection with baculovirus, Sf9 cells containing
recombinant enzymes were collected by centrifugation
at 2,000g for 10 min., and frozen at -80°C until use. The
procedure for purifying N-His6-PSA is similar to that as
previously described [21]. Briefly, a cell paste was sus-
pended in 10 volumes of lysis buffer (20 mM Tris buf-
fer, pH 7.5, 1 mM PMSF and 10 μME - 6 4 )a n d
sonicated with a Branson Sonifier 450 (Output control
at 4, Duty cycle 30%, 10 sec for 3 times). The homoge-
nate was centrifuged 30 min at 30,000g and the superna-
tant applied to a Waters Acell Plus QMA anion
exchange column (15 mL) in 20 mM Tris buffer, pH
7.5. Proteins were eluted with a 0 to 0.5 M linear NaCl
gradient with PSA eluting at ~0.11 M NaCl. The eluted
enzyme was concentrated and applied to a Pharmacia
Superdex 200 column (1.6 cm × 60 cm) equilibrated
and run with 20 mM Tris buffer, pH 7.5. The active
PSA fractions were pooled, and concentrated with a
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cerol at -80°C.
For purifying C-His6-PSA, cell pellets were sonicated
as described above with 300 mM NaCl and 5 mM imi-
dazole included in the buffer. The supernatant was
passed through a 5-ml His-Select Nickel affinity column
and eluted with 100 mM imidazole. After concentration
and buffer exchange the purified enzyme was made 20%
glycerol and stored at -80°C.
PSA was also expressed in E. coli as GST and MBP
fusion proteins. The expression vectors pET41, which
contains a GST sequence and a TEV protease cleavage
site and pETa-MBP [22], which contains a His8-Maltose
binding protein and a TEV cleavage site were used.
These plasmids were transformed into E. coli BL-21
(DE3)-RP and the bacteria were allowed to grow until
an OD600 of 0.5 to 0.7 was reached. PSA expression was
induced by the addition of IPTG to a final concentration
of 0.5 mM, and carried out overnight at 16°C, after
which time cells were harvested, washed with PBS and
stored at -20°C. A GST Prep FF 16/10 column (GE
Health Science) was used to purify GST-PSA as pre-
viously described [21]. Purified GST-PSA was treated
overnight with TEV protease at 4°C to remove GST and
further purified by chromatography on an S-200 (GE
Health Science) gel filtration column. GST-PSA, without
being treated with TEV protease, was also chromato-
graphed on the same column. His8-MBP-PSA was puri-
fied by chromatography on Ni resin as described above
followed by S-200 chromatography. The active fractions
were concentrated and treated with TEV protease to
remove His8-MPB. Lastly the enzyme was purified on a
1-mL 15Q anionic exchange resin (GE Health Science).
Lentivirus production
cDNAs for human PSA and an inactive E309A point
mutant (PSAx) [20] were subcloned into the lentiviral
vector pCSC-SP-PW. Lentiviruses were then produced
using a four-plasmid transfection system as described
previously [23].
Aminopeptidase activity assays
Aminopeptidases were routinely assayed using 20 μM
alanine 4-methoxy-2-naphthylamine (Ala-4-MNA) as
substrate in 25 mM Tris-HCl buffer, pH 7.5. Free
4-MNA released by PSA was monitored on a fluorescent
plate reader (GX, Molecular Device) at an excitation of
340 nm and an emission of 425 nm. Hydrolysis of Leu-
enkephalin (YGGFL) was determined by reverse phase
HPLC on a Phenomnex C18 column (5.0 × 4.6 mm) by
following its disappearance at 214 nm. Products were
separated by a linear gradient from 0.1% trifluoroacetic
acid in 95% water/5% acetonitrile to 0.1% trifluoroacetic
acid in 50% water/50% acetonitrile.
Tau degradation in cells
HEK293 cells expressing a tetracycline-inducible human
2N4R Tau were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum, 5 μg/
ml blasticidin and 400 μg/ml zeocin [24]. For overexpres-
sion of human PSA, the cells were transduced with a PSA
expressing lentivirus and cultured for 48 hrs. As controls,
lentiviruses expressing GFP or an inactive point mutant of
PSA (PSAx) were used. To induce Tau expression, 1 μg/
ml tetracycline was added to the media and cells were col-
lected 12 hrs later. Cells were lysed in 50 mM Tris HCl,
pH 8.0, 150 mM NaCl, 1% NP40 containing complete pro-
tease inhibitors cocktail (Roche). The lysate was subjected
to SDS-PAGE and Western blot analysis.
Electrophoresis and Western Blot Analysis
SDS-PAGE [25] was conducted using a Bio-Rad Protean
system. Proteins were stained with Coomassie Blue R250
(Sigma-Aldrich). The BioRad Precision Plus All Blue Pro-
tein standard was used for estimating molecular weight.
Density of protein bands were assessed using ImageJ soft-
ware [26]. For Western analysis, gels were transferred
onto a polyvinyldifluoride membrane (Millipore) accord-
ing to Towbin [27]. The dilutions of primary antibodies
were 1:5,000 for antibody 5A6 and 1:8.000 for antibody
A2400. Proteins were detected and quantified using a Li-
COR Odyssey Imaging system with the following second-
ary antibodies: Alexa Fluor 680 goat anti-mouse IgG (Life
Technologies) and IRDye 800 conjugated affinity purified
goat anti-rabbit IgG (Rockland).
Protein assay
Protein concentration was determined using Coomassie
Plus (Pierce Chemical Company). Bovine serum albumin
was used as the protein standard.
Identification of protein fragments by Mass Spectrometry
Protein bands were identified by mass spectrometry at
t h eU n i v e r s i t yo fK e n t u c k yP r o t e o m i c sc o r ew i t h i nt h e
Center of Structure Biology. This facility is supported in
part by grant P20RR020171 from the NIH NCRR.
Briefly, gel bands were excised from SDS-PAGE,
digested with Sigma proteomics grade trypsin, and alky-
lated with iodoacetamide. Samples were then analyzed
with an Applied Biosystems 4800 MALDI TOF/TOF
Proteomics Analyzer. MALDI MS spectra were used for
analyzing Tau products. For unknown proteins, MS/MS
spectra were used to search against the Uniprot_-
sprot_20100125+ contams.fasta database through Pro-
tein Pilot (Applied Biosystems) Ver. 2.0, Rev. 50861.
Results
We initially tested the reaction of purified recombinant
human PSA expressed in Sf9 insect cells with Tau. This
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ing an N-terminal hexahistidine affinity tag (N-His6-
hPSA) as previously described [20]. The purity of
N-His6- h P S Aw a se s t i m a t e dt ob e~ 9 0 %a sj u d g e df r o m
a Coomassie stained SDS-PAGE gel, figure 1a. After
removal of the affinity tag this purified hPSA (hPSA
Sf)
was tested for its ability to hydrolyze Tau by incubation
with recombinant Tau 0N4R for 16 hours at 37°C at a
molar ratio of Tau to PSA of 15:1 as described by Kar-
sten et al. [11]. Cleavage of Tau was apparent as
assessed by Coomassie blue protein staining of the reac-
tion subjected to SDS-PAGE, figure 1b. To further ana-
lyze the reaction, major products shown in figure 1b
were analyzed by peptide mass spectral fingerprinting.
The identified peptides from these products are listed in
Table 1. Additionally, degradation products were reacted
with antibodies specific to the N-and C-terminal regions
of Tau (figure 1c). Since hPSA
Sf is an exopeptidase that
cleaves amino acids sequentially from the N-terminus,
we were surprised to find that reaction products, N1 to
N3, which were decreased in size by apparent molecular
weights of greater than 15 kDa, still retained the epi-
topes for the N-terminally directed antibody 5A6. The
identified peptides (Table 1) agree with that of Western
analysis in that the N-terminus of these cleavage pro-
ducts is intact. This finding shows that Tau cleavage
was internal, not expected for an aminopeptidase.
We also identified four C-terminal peptides derived
from the PSA cleavage reaction (C1 through C4).
Although these fragments could result from sequential
amino acid release from the N-terminus, the number
a n ds i z eo ft h eb a n d sd e t e c t e db yt h eC - t e r m i n a lT a u
antibody A0024 makes this unlikely. This follows since
one would expect a series or ladder of products detected
by the C-terminal antibody rather than discreet pep-
tides. figure 2 schematically superimposes the identified
Figure 1 Human PSA
sf preparation cleaves Tau. (a) Purity of hPSA
sf (5 μg). (b) Degradation of Tau by hPSA
sf. Tau was incubated with PSA at
a molar ratio of 15:1 (Tau:PSA) in 10 mM Tris buffer, pH 7.5, 1 mM DTT at 37°C for 16 h. Reactions containing 1 μg Tau were analyzed by SDS-
PAGE on a 12.5% gel. Labeled products and intact Tau were further analyzed by mass spectrometry and the result is shown in Table 1. (c)
Reaction products immunoblotted with N-terminal Tau antibody 5A6 (red) or C-terminal Tau antibody A00024 (green). Twenty percent of the
reaction mix was loaded in each lane. Intact Tau shows a yellow color due to the red/green overlap. N1 also reacts to A00024, but was
overshadowed by higher intensity signal of 5A6. Molecular weight markers in kDa are shown at the left.
Table 1 Identification of Tau degradation products by
mass spectral peptide fingerprinting
Protein Band Calc’d
(M+H
+)
Expt’l
(M+H
+)
Peptides identified
N1 2069.89 2069.67
6QEFEVMEDHAGTYGLGDR
2181.90 2181.74
25DQGGYTMHQDQEGDTDAGLK
2424.13 2424.89
45AEEAGIGDTPSLEDEAAGHVTQAR
1393.63 1393.50
137SGYSSPGSPGTPGSR
842.55 842.43
217VQIINKK
1980.09 1979.87
241HVPGGGSVQIVYKPVDLSK
N3 2069.89 2069.81
6QEFEVMEDHAGTYGLGDR
2424.13 2424.05
45AEEAGIGDTPSLEDEAAGHVTQAR
1393.63 1393.61
137SGYSSPGSPGTPGSR
1066.59 1066.55
154TPSLPTPPTR
842.55 842.50
217VQIINKK
C1 1420.78 1420.64
154TPSLPTPPTREPK
842.55 842.48
217VQIINKK
1974.00 1973.90
264CGSLGNIHHKPGGGQVEVK
1578.82 1578.76
296IGSLDNITHVPGGGNK
978.54 978.51
318LTFRENAK
1101.55 1101.52
338SPVVSGDTSPR
1381.66 1381.61
381QGLLEHHHHHH
C3 842.55 842.44
217VQIINKK
1578.82 1578.67
296IGSLDNITHVPGGGNK
978.54 978.46
318LTFRENAK
1101.55 1101.45
338SPVVSGDTSPR
1381.66 1381.54
381QGLLEHHHHHH
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cleavage sites are located in the vicinity of the four
microtubule-binding motif repeats.
We found that the hPSA
Sf dependent cleavage of Tau
was not blocked by the aminopeptidase inhibitors besta-
tin and puromycin, but was inhibited by the metal che-
lator o-phenanthroline (figure 3). Puromycin rather than
inhibit had an activation effect on the reaction. As a
control we showed that the reaction of hPSA
Sf with two
known PSA substrates, alanine 4-methoxy-2-naphthyla-
mide (Ala-4-MNA) and Leu-enkephalin, was completely
inhibited by bestatin and puromycin under the same
conditions in which these inhibitors failed to inhibit Tau
cleavage, (Table 2). The finding of endopeptidase-like
cleavage of Tau, the insensitivity of the reaction to PSA
inhibitors, together with the sensitivity of the reaction to
the metal chelator o-phenanthroline suggest either con-
tamination of the hPSA
Sf preparation with a metallo-
endopeptidase that cleaves Tau or that the cleavage of
Tau by hPSA
Sf proceeds through a novel mechanism.
In an attempt to resolve this issue we expressed hPSA
in E. coli assuming that if the cleavage of Tau was due
to a contaminating protein derived from Sf9 cells it
would be highly unlikely that the same or similar con-
taminant would be present in enzyme preparations
derived from a totally different system. We thus
expressed hPSA as two different fusion proteins, a
glutathione S-transferase fusion protein (GST-hPSA)
and a-maltose binding protein fusion protein (MBP-
hPSA). Since N-His6-hPSA did not bind well to a nickel
resin and was purified conventionally, an additional
form of PSA containing a C-terminal His6 tag (C-His6-
PSA) was expressed in Sf9 insect cells and purified on a
Figure 2 Diagrammatic presentation of Tau (0N4R) degradation and the possible cleavage regions. Degradation products were drawn
based on Western analysis (Figure 1b). Identified peptides (Table 1) from the corresponding protein bands (Figure 1a) are shown as white
arrows.
Figure 3 Hydrolysis of Tau by hPSA
Sf in the presence of
protease inhibitors. hPSA
sf was preincubated with protease
inhibitors on ice for 15 min, and then tested for activity towards
Tau as described in Figure 1.
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parations derived from Sf9 cells or E. coli were essen-
tially the same, ~6 μmol of 4-MNA released from Ala-
4-MNA per min per mg protein. Equal amounts of PSA
activity from these different preparations was tested for
their ability to cleave full-length Tau 2N4R, since it has
been previously reported [11,12] that the 2N4R isoform
is cleaved by hPSA
GST with or without the GST
removed. We used the same reaction conditions as
described [11], which included 10 mM Tris buffer, pH
7.5 and 1 mM DTT. When tested, with the exception of
the original hPSA
Sf (N-His6-hPSA with His tag
removed), none of these other PSA preparations cleaved
Tau 2N4R, figure 4. An identical result was obtained
when Tau 0N4R was used as a substrate, figure 4b.
Thus, it is very likely that the N-His6-hPSA preparation,
being the only one of four different PSA preparations
that cleaved Tau, contains a contaminating protease
responsible for Tau cleavage.
Next, we attempted to resolve PSA activity from Tau
cleaving activity in the N-His6-hPSA
Sf preparation.
A preparation of N-His6-hPSA
Sf was purified from an
Sf9 cell extract following the purification scheme
described in Methods. At the final molecular sieve pur-
ification step PSA activity toward the synthetic sub-
strate Ala-4-MNA and Tau cleaving activity were
assayed in fractions collected from the S200 column.
As shown in figure 5a, Tau activity was eluted in a
broad peak with maximal activity at fraction 27. In
contrast true PSA activity as measured with Ala-4-
MNA peaked at fraction 29. Despite the fact that elu-
tion of Tau cleaving activity exhibits a broad peak that
overlaps with PSA activity, these activities are clearly
distinguishable. For example, Tau cleaving activity is
approximately the same in fractions 27 and 29, but
aminopeptidase activity in fraction 29 was ~35 times
higher than that of fraction 27.
As a further control we examined Tau cleaving activ-
ity in extracts from untransfected Sf9 cells taken
through the same purification scheme. As shown in fig-
ure 5b (upper panel) Tau cleaving activity was detected
in a similar elution profile in naive cells as seen when
PSA was expressed. This shows the presence of endo-
genous Tau cleaving activity in Sf9 cells that likely con-
taminated our purified N-His6-hPSA
Sf preparation. To
determine whether PSA, rather than cleave Tau, might
activate Tau cleavage by a contaminating protease, we
added C-His6-PSA, known to have aminopeptidase
activity but no Tau cleaving activity, to each of the Tau
cleaving untransfected Sf9 derived fractions. As seen in
figure 5b (lower panel), the Tau degradation profile was
not altered by the additional of C-His6-PSA.
We attempted to identify other protein bands in the
hPSA
Sf preparation that might cleave Tau by subjecting
the N-His6-hPSA
Sf preparation to SDS-PAGE, cutting
out gel slices, and using peptide mass spectral finger-
printing to identify protein contaminants. Although
there were trace proteins present, due to the lack of a
Spodoptera frugiperda protein database, only an insect
heat shock protein (~70 kd) was identified as a contami-
nant based on its homology to the Cercopia moth
protein.
Table 2 Inhibition of PSA
sf Tau cleaving activity by
protease inhibitors
Substrate % Activity Remaining
Bestatin Puromycin o-phenanthroline PMSF
(2 mM) (2 mM) (2 mM) (2 mM)
Alanine 4MNA 0 0 0 79
Dynorphin A 0 0 0 79
PSA
sf was preincubated with protease inhibitors at 2 mM on ice for 15 min.
PSA activity was then assayed with alanine 4MNA, Dynorphin A. PSA
sf
incubated with buffer was taken as 100% to determine the remaining PSA
activity of each treatment.
Figure 4 Reaction of Tau with various forms of PSA.S a m e
amount of PSA activity was reacted with Tau 2N4R or Tau 0N4R in
10 mM Tris buffer, pH 7.5, 1 mM DTT at 37°C for 16 h. (a). Reaction
mixtures were analyzed by SDS-PAGE, only Tau 2N4R is shown. (b).
For quantitation, the intensity of Tau remaining was determined
using ImageJ software [26]. For internal control, a 50% Tau alone
(last lane) was run and the band intensity shown to be ~50% of the
input Tau (first lane). Further, by analyzing the staining intensity of
the PSA bands we calculated that the variation in the amount of
PSA added in each lane varied less than 4%. For the GST-PSA lane,
both GST-PSA and free PSA were present. Their intensities were
combined to get total PSA. * = free GST.
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Page 6 of 10Figure 5 Separation of aminopeptidase and Tau-cleaving activities on an S-200 column. (a). PSA derived from Sf9 cells was purified as
described in Methods. Following an anionic QMA column, the enzyme was chromatographed on an S-200 column and fractions were assayed
for both Tau and aminopeptidase activity. The arrows show the eluted PSA activity detected on the gel. Tau activity is shown as the %
hydrolysis (solid square), while aminopeptidase activity toward alanine 4-MNA is shown by solid triangles. (b). An Sf9 cell extract from non
infected cells was fractionated the same way as the above. Upper panel: Fractions assayed for Tau-cleaving activity. Lower panel: Fractions
assayed for Tau-cleaving activity in the presence of exogenous C-His6-PSA with a molar ratio of Tau:PSA (5:1).
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Tau in a cellular context, we transduced HEK 293 cells
expressing a tetracycline-inducible human 2N4R Tau
with a lentivirus expressing PSA. As controls lentiviruses
expressing GFP or an inactive point mutant of PSA
(PSAx) were used. The expressed PSA had no effect of
the intracellular level of Tau under steady-state expres-
sion conditions (figure 6A) or when Tau expression was
induced (figure 6B).
We tested the reactivity of another aminopeptidase,
aminopeptidase N (ApN) with Tau because it is a related
protein with very similar kinetics and substrate specificity
to PSA [16]. Surprisingly, we found that a commercial
purified porcine ApN preparation cleaved Tau. To deter-
mine whether the Tau cleaving activity is caused by ApN,
we fractionated this ApN preparation by hydrophobic
chromatography on a TosoHaas butyl-650 column and
tested the reactivity of the eluted fractions toward Tau
and toward the aminopeptidase substrate Ala-4-MNA.
The results showed that aminopeptidase activity and
Tau-cleaving activity are clearly resolved (figure 7),
demonstrating that aminopeptidase N does not hydrolyze
Tau. Attempts to identify the Tau-cleaving enzyme by
mass spectral fingerprinting also met the same difficulty
as with the insect protein, namely a lack of an adequate
database. Unfortunately only ~300 porcine DNA
sequences are currently deposited in the NCBI database,
and none of those showed up in our analysis. Thus the
identification of the Tau cleaving enzymes derived both
Sf9 cells and from porcine kidney remains unknown, but
is clearly not PSA.
Discussion
In this study several lines of evidence have been
obtained which show that the puromycin sensitive ami-
nopeptidase does not directly cleave Tau. (i) The clea-
vage pattern obtained with Sf9 derived N-His6-hPSA is
inconsistent with aminopeptidase cleavage. (ii) Several
PSA preparations derived using different expression sys-
tems and purification methods do not cleave Tau. Only
the preparation obtained from Sf9 cells containing an
N-His6-affinity tag cleaves Tau. The N-His6 affinity tag
containing PSA was the only form that was not purified
by affinity chromatography. (iii) Aminopeptidase and
Tau-cleaving activity can be separated by gel filtration
chromatography for PSA and by hydrophobic chromato-
graphy for the related aminopeptidase N. (iv) Within a
cellular context increasing PSA expression did not affect
Tau steady-state levels. Thus, we are forced to conclude
that PSA does not cleave Tau and that the Tau-cleaving
activity we observed in our PSA preparation is caused
by an as yet unidentified contaminating protease. Since
this activity was inhibited by o-phenanthroline this con-
taminating protease is likely a metalloprotease.
Our finding that PSA does not cleave Tau appears at
variance with several published reports [11,12,28].
Although our purified PSA preparations, including the
Figure 6 PSA does not cleave Tau in cells. HEK293 cells expressing a tetracycline-inducible 2N4R Tau were transduced with lentivirus
expressing GFP, PSA or its inactive mutant form (PSAx) and cultured for 48 hrs. Tetracycline (1 μg/ml) [Tet(+)] or vehicle (1:1 vol/vol water/
ethanol) [Tet(-)] was added and cells were collected 12 hrs later. Cell extracts were subjected to SDS-PAGE, and analyzed by Western blot
analysis with goat anti-hPSA (Chemicon) at 1:2000, and mouse anti-Tau antibody 5A6, at 1:4000. This was followed by incubation with
peroxidase conjugated secondary antibodies and ECL Western Blotting detection.
Figure 7 Separation of aminopeptidase N from Tau-cleaving
activity. A commercial preparation of aminopeptidase N was
fractionated on a butyl S-650 hydrophobic chromatography. (a).
Tau-cleaving activity was estimated by the intensity of the
remaining Tau band as analyzed by SDS-PAGE. T = Tau with buffer
only. (b) Aminopeptidase N activity as determined with alanine
4MNA as substrate.
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Page 8 of 10same GST fusion protein previously studied [11] did not
cleave Tau, it is still possible that PSA regulates Tau
cleavage by an indirect mechanism. Studies in
TauP301L transgenic mice in conjunction with a func-
tional analysis in Drosophila associate Tau as being
r e g u l a t e db yP S A[ 1 1 ]a n dar e c e n tr e p o r ts h o w e dt h a t
using an interference RNA against PSA increased Tau
levels in SH-SY5Y cells [28]. However as shown in this
study over expression of PSA in HEK cells did not
change Tau levels. Since we conclude that PSA does not
directly cleave Tau, the regulation of Tau levels by PSA
might work through its interaction with other proteins
or by regulating the level of a peptide that facilitates
Tau cleavage. For example it has been shown that PSA
works in conjunction with the proteosome dependent
degradation of polyglutamine containing proteins by
cleaving the released polyglutamine peptides [29].
Understanding the mechanism by which PSA affects
Tau levels will clearly require additional studies.
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